Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.40 |
| ▸ | PPARG | P37231 | 9/20 | 0.40 |
| ▸ | PPARD | Q03181 | 7/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553504 | 0.92 | CTSL (0.40) | PPARAPPARGPPARDAPEX1AKR1B1 | |
| SCHEMBL5552247 | 0.89 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL5553514 | 0.88 | PPARA (0.46) | PPARAPPARGPPARDMMP2 | |
| SCHEMBL5552733 | 0.87 | PPARA (0.41) | PPARAPPARGPPARDAPEX1MMP2 | |
| SCHEMBL5553481 | 0.84 | PPARA (0.48) | PPARAPPARGPPARDAPEX1MMP2 | |
| SCHEMBL6496012 | 0.83 | PPARA (0.57) | PPARAPPARGPPARD | |
| SCHEMBL5549070 | 0.82 | ACACB (0.37) | PPARAPPARGPPARD | |
| SCHEMBL5554858 | 0.79 | PPARA (0.42) | PPARAPPARGPPARDAPEX1 | |
| SCHEMBL5554894 | 0.79 | PPARA (0.46) | PPARAPPARGPPARDMMP2AKR1B1 | |
| SCHEMBL5549733 | 0.79 | APEX1 (0.39) | PPARAPPARGPPARDAPEX1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20040138271-A1 | Benzene compound and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1375472-A1 | BENZENE COMPOUND AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138271-A1 | Benzene compound and salt thereof | INSR, SLC5A1, IRS1 | PPARA 602/4885PPARG 620/4885PPARD 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.